>>Signaling Pathways>> Proteases>> ACE>>Imidaprilate (6366A)

Imidaprilate (6366A)

Catalog No.GC32600

이미다프릴레이트(6366A)는 TA-6366의 활성 대사물로 IC50이 2.6nM인 강력한 안지오텐신 전환 효소(ACE) 억제제로 작용하며 고혈압 질환 연구에 사용됩니다.

Products are for research use only. Not for human use. We do not sell to patients.

Imidaprilate (6366A) Chemical Structure

Cas No.: 89371-44-8

Size 가격 재고 수량
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Imidaprilate is an active metabolite of TA-6366, acts as a potent angiotensin converting enzyme (ACE) inhibitor, with an IC50 of 2.6 nM, and is used in the research of hypertensive disease.

Imidaprilate (6366A) is an active metabolite of 6366, acts as a potent angiotensin converting enzyme (ACE) inhibitor, with an IC50 of 2.6 nM. Imidaprilate augments the bradykinin-induced contraction of guinea pig ileum, with AC50 of 1.7 nM[1].

Imidaprilate (≥0.2 mg/kg) inhibits angiotensin I (AT-I)-induced pressor response. TA-6366 lowers the blood pressure in two-kidney one-clip renal hypertensive rats at 0.5-2 mg/kg via oral administration, and in spontaneously hypertensive rats (SHRs) at 2 to 10 mg/kg[1].

[1]. Kubo M, et al. Pharmacological studies on (4S)-1-methyl-3-[(2S)-2-[N-((1S)-1-ethoxycarbonyl-3-phenylpropyl)amino] propionyl]-2-oxo-imidazolidine-4-carboxylic acid hydrochloride (TA-6366), a new ACE inhibitor: I. ACE inhibitory and anti-hypertensive activities. Jpn J Pharmacol. 1990 Jun;53(2):201-10.

리뷰

Review for Imidaprilate (6366A)

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Imidaprilate (6366A)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.